Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension Amendment PR Newswire NEW YORK, Jan. 4, 2023 NEW...
Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, today announced that Wendye...
Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement PR Newswire NEW YORK and SOUTH SAN FRANCISCO, Calif., June 13, 2022 NEW YORK and...
Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination PR Newswire NEW YORK and SOUTH SAN...
Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination PR Newswire NEW YORK and SOUTH SAN...
Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade...
Cudetaxestat displayed direct anti-fibrotic effects on multiple biomarkers in a preclinical lung fibrosis model Non-competitive autotaxin inhibition by cudetaxestat maintained potency in the...
No significant drug-drug interaction (DDI) seen with cudetaxestat in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF...
Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business...
Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc. PR Newswire NEW YORK, April 4, 2022...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
